Andrew McConaghie

The rheumatoid arthritis failure for its TL1A antibody was not unexpected and analysts see the US biotech's attempt to develop two-drug combinations in ulcerative colitis as its best chance in a crowded field.

The Swiss biotech still has big pharma partnerships in Alzheimer's disease but is putting more focus on developing its in-house pipeline, especially in Parkinson's disease

Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.

Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso's dominance in EGFR-mutated lung cancer treatment

Its initial filing was rejected in April by the FDA's now-departed Vinay Prasad but a new leadership agrees with UniQure that a new sham-controlled trial is not necessary raising hopes that its first product could soon be approaching the market.

Now approved in pancreatic cancer, Revolution is hoping to extend the use of Rasonque into non-small cell lung cancer, alongside developing its other more mutation-specific RAS inhibitors in the pipeline.

Another blow for Novo after data monitoring committee sees little hope of success for the anti-inflammation drug ziltivekimab in two further trials.

Novo Nordisk and Novartis have both been dealt big blows by the recent failure of their major cardiovascular outcome studies. More CVOT readouts for novel agents are on the way but the bar for success keeps being raised.

Two cardiovascular outcomes study failures could wipe $3.9bn from cardiovascular pipeline forecasts as Novartis's pelacarsen and Novo Nordisk's ziltivekimab become the latest casualties of a rising standard of care.

The San Diego-based biotech is hot on the heels of its Californian neighbor, and believes its ERAS-0015 could show a safety and efficacy edge over Rasonque.